Screening for Giardia/Cryptosporidium infections using an enzyme immunoassay in a centralized regional microbiology laboratory.

CONTEXT: Stool parasitologic testing for Giardia and Cryptosporidium (G/C) previously relied on staining (ie, modified iron hematoxylin-kinyoun), ethyl acetate concentration procedures, and microscopy (the stool ova and parasite method). In April 1999, a microplate enzyme immunoassay (EIA) (ProSpecT G/C, Remel, Inc, Lenexa, Kan) for routine screening of all stool specimens was implemented. OBJECTIVE: To determine the clinical and laboratory impact of this service change. DESIGN: Changes were made to the regional microbiology requisition so that physicians could order either a G/ C EIA screen or stool ova and parasite examination. During a 3-year period (May 1999 through April 2002), changes in physician ordering practice, the rate of detection of G/ C infections, and test turnaround times were monitored. The economic outcomes have also been studied and compared annually since implementation and up to the current fiscal year (2004). RESULTS: The following effects have been noted since G/ C EIA screening was implemented: (1) 70% of all stool parasite tests ordered were converted to G/C EIA screens versus stool ova and parasite tests, (2) stool parasitologic volumes decreased by up to 30% because of physicians ordering a single test per patient, (3) most stool parasite results (70%-80%) were reported within 24 hours of specimen receipt, and (4) the screening assay has improved detection of cryptosporidiosis cases. Although the G/C EIA tests cost more than stool ova and parasite examination, the equivalent of 1.8 full-time employees have been freed up to perform other duties. CONCLUSIONS: Routine stool G/C EIA screening in our region is not only clinically relevant but also improves the timeliness and efficiency of detection of these important enteric parasite infections.

Reasons for testing women for genital Chlamydia trachomatis infection in the Calgary region.

OBJECTIVE: To determine the clinical reason(s) for screening women with varying degrees of risk for genital Chlamydia trachomatis (CT) in the Calgary region. DESIGN: Women aged 15 to 75 years were enrolled at various patient care locations. Pertinent risk factors for genital CT infection were recorded and a gynecological examination was performed. Two endocervical swabs and a first-void urine sample were collected for CT detection using two different nucleic acid amplification test methods. SETTING: Calgary is an urban region that provides healthcare services to a population of almost one million people. Microbiology services are provided by Calgary Laboratory Services through a centralized regional laboratory service. MAIN RESULTS: 504 women with a mean age of 28.1 +/-SD 8.22 years were enrolled. Two hundred ninety-one women (57.8%) were at high risk for acquiring genital CT infection. Twenty-eight (5.6%) tested positive for CT infection and almost all of these women (26 of 28, 93%) had risk factors for acquiring infection. Of the high-risk women, 9.8% were CT positive versus only 1.3% of women at low risk (P=0.0001). Only two of 152 (1.3%) women older than 30 years had genital CT infections. Although most women were asymptomatic, those with laboratory-confirmed CT infection were more likely to have genitourinary symptoms. Three hundred forty-three of 476 (72%) women who did not have genital CT infection had no risk factors, and screening was done as part of a routine gynecological examination for other purposes (prenatal visit, Pap smear). CONCLUSION: Women without risk factors are being screened routinely for genital CT infection as part of a routine gynecological examination done for other reasons. Elimination of the routine screening of low-risk women older than 30 years of age would decrease the current regional utilization of CT tests by as much as one-third.

Evaluation of the Coral UTI Screen system for rapid automated screening of significant bacteriuria in a regional centralized laboratory.

An evaluation of the Coral UTI screen system (Coral Biotechnology, San Diego, CA) compared to urinalysis/urine culture was done to assess its performance for rapidly screening a high volume of urine samples for significant bacteriuria in a regional central microbiology laboratory. A total of 1094 urine samples from ambulatory patients were evaluated. 670 (61.2%) urine samples were negative or positive [178 (16.3%)] by both methods. 217 (19.8%) other samples were UTI screen positive but had either no growth or no uropathogens on culture; 9 of these samples were possibly false negative by culture because of the presence of pyuria, indicating the presence of either a urinary tract infection or another inflammatory process. Another 29 (2.7%) samples had false negative screens because the urine culture was positive, but only 5 of these patients were treated with antibiotics after urine specimen collection. Overall, the Coral UTI screen has a sensitivity of 86.0%, a specificity of 75.5% and a positive and negative predictive value of 45.0% and 95.9% respectively. Routine use of the UTI screen would allow same day reporting of 65% of all urine culture results without having to proceed to culture.

Clinical and economic evaluation of rapid influenza a virus testing in nursing homes in calgary, Canada.

The incremental benefits and costs of a rapid influenza A virus infection diagnostic service were studied in nursing homes in Calgary, Canada, during a single influenza season. The service was used to test 159 patients with suspected infection in a group of "experimental" nursing homes and results were compared with those for a group of "control" homes. An equal number of cases of influenza were identified in each group. Twenty-eight patients (17.6%) had confirmed cases, and 63 patients (39.6%) had probable cases. A rapid viral test result was provided much faster for patients in the experimental homes (P=.005). Both groups had the same median attack rate for influenza A virus. In experimental homes, the duration of the outbreak was shorter (P=.03), and the cost of laboratory testing and the total cost (less the hospital cost) tended to be lower (P<.2). The rapid testing service also tended to lower the overall use of resources.

Evaluation of sequential testing strategies using non-amplified and amplified methods for detection of Chlamydia trachomatis in endocervical and urine specimens from women.

Nucleic acid amplification tests (NAAT) are more sensitive than other methods for the diagnosis of Chlamydia trachomatis (CT) genital infections. Two unique sequential testing strategies that employed two different commercial NAAT methods to detect CT in a population of women with widely varying infection risk were evaluated. Specimens from 504 women aged 15 to 75 years were studied. Two endocervical swabs and a urine sample were collected from each woman. One swab was initially tested using the Access enzyme immunoassay (EIA) (Beckman). An aliquot from the EIA extraction was subsequently amplified using the COBAS AMPLICOR CT assay (PCR) (Roche). The second swab was initially tested using the PACE 2 CT hybridization assay (Gen-Probe). An aliquot was pipetted off prior to performing the PACE 2 assay and also amplified using the AMP-CT assay (TMA) (Gen-Probe). Urine samples were tested for CT using both NAAT methods. True CT infections were defined as any woman that was confirmed to be positive on both NAAT results from endocervical swabs. The results of all other CT assays were compared against this expanded gold standard. 28 women were confirmed to have CT infection giving an overall prevalence of 5.6%; low-risk women had a rate of 1.3% while high-risk women had a rate of 9.8%. NAAT methods have a higher sensitivity for detecting CT cervicitis when swabs are tested compared to urine. The positive predictive value of NAAT is decreased when testing low risk women. Limited automation makes it difficult to test a high volume of samples (i.e., > 100 swabs and/or urines) using either of these NAAT methods and continue to provide same day results. Laboratories performing CT testing must define the female population served so that appropriate diagnostic strategies can be employed.